Top 50 High-Quality Dividend Stocks For September 2025

A proprietary universe of 50 high-quality dividend growth stocks posted a YTD return of +10.16% as of September 5, 2025, slightly underperforming SPY (+10.37%) but significantly outpacing SCHD (+3.12%). The analysis identified 23 stocks with attractive future return estimates exceeding 10%, with 12 of these also presenting as undervalued via a Free Cash Flow model. ResMed, with an 18.86% estimated return, leads the top-ranked opportunities, underscoring the systematic identification of fundamentally strong, attractively valued dividend growth investments.

Analysis

A proprietary universe of 50 high-quality dividend growth stocks has demonstrated performance closely aligned with the broader market, posting a year-to-date return of 10.16% as of September 5, 2025, versus 10.37% for the SPDR S&P 500 ETF (SPY). However, this curated portfolio has significantly outpaced the Schwab U.S. Dividend Equity ETF (SCHD), which returned only 3.12% over the same period, suggesting the selection methodology adds value over a passive dividend strategy. The core of the strategy is a Free Cash Flow (FCF) valuation model that has identified 12 stocks as both potentially undervalued and offering estimated forward returns exceeding 10%. Among these, ResMed (RMD) is ranked highest with an 18.86% estimated return, driven by strong projected EPS growth (11.18%) and a current FCF yield 39% above its trailing average. The list of attractive stocks exhibits significant performance divergence; for example, top-ranked MarketAxess (MKTX) is down 18.07% YTD, while third-ranked Ferrari (RACE) is up 13.13% YTD, indicating the model identifies potential value in both out-of-favor names and strong performers.

Key Decisions for Investors

• Investors should consider the 12 highlighted stocks, particularly top-ranked names like ResMed (RMD) and MarketAxess (MKTX), as a pre-screened list for potential long positions in the dividend growth space, given their favorable FCF valuation and double-digit forward return estimates.
• The significant YTD underperformance of several highly-rated stocks, such as Accenture (ACN, -25.02%) and West Pharma (WST, -24.43%), suggests these could be contrarian value opportunities, warranting further due diligence to confirm the model's thesis against prevailing market sentiment.
• Given the proprietary universe's outperformance against the SCHD ETF, investors may find this quality and FCF-based screening approach more effective for sourcing individual dividend growth ideas than relying on broad, passive dividend-focused ETFs.
• Evaluate the primary drivers of projected returns for each target; for instance, Ferrari's (RACE) return is dominated by high projected EPS growth (14.00%), whereas MarketAxess's (MKTX) depends more heavily on a reversion to its estimated fair value, implying different risk profiles and investment theses.